Alto Neuroscience (NYSE:ANRO) Earns “Outperform” Rating from William Blair

William Blair reissued their outperform rating on shares of Alto Neuroscience (NYSE:ANRO) in a report released on Friday morning,RTT News reports.

Alto Neuroscience Stock Performance

Shares of ANRO opened at $2.71 on Friday. Alto Neuroscience has a 1-year low of $2.58 and a 1-year high of $18.35. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. The firm’s 50-day moving average price is $3.63 and its 200-day moving average price is $6.15.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.09. As a group, equities analysts expect that Alto Neuroscience will post -2.54 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

A number of hedge funds have recently modified their holdings of ANRO. Wells Fargo & Company MN grew its stake in shares of Alto Neuroscience by 40.0% in the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock worth $46,000 after buying an additional 3,139 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Alto Neuroscience by 619.2% in the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after acquiring an additional 3,715 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of Alto Neuroscience by 31.3% during the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after acquiring an additional 3,629 shares in the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Alto Neuroscience in the 4th quarter worth about $74,000. Finally, Jane Street Group LLC boosted its stake in Alto Neuroscience by 72.0% in the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company’s stock worth $79,000 after purchasing an additional 7,783 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.